15-Deoxy-Δ12,1412,14-prostaglandins D2 and J2 Are Potent Activators of Human Eosinophils
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
15-Deoxy-Δ12,14-PDJ2 (15d-PGJ2) is a degradation product of PGD2 that has been proposed as an anti-inflammatory compound because of its various inhibitory effects, some of which are mediated by peroxisome proliferator-activated receptor-γ. In contrast to its reported inhibitory effects on macrophages and other cells, we found that this compound is a potent activator of eosinophils, inducing calcium mobilization, actin polymerization, and CD11b expression. It is selective for eosinophils, having little or no effect on neutrophils or monocytes. 15d-PGJ2 has an EC50 of ∼10 nM, similar to that of its precursor, PGD2. The concentrations of 15d-PGJ2 required to activate eosinophils are thus much lower than those required for its anti-inflammatory effects (usually micromolar). 15-Deoxy-Δ12,14-prostaglandin D2 (15d-PGD2) is also a potent activator of eosinophils, with an EC50 about the same as that of PGD2, whereas Δ12-PGJ2 is slightly less potent. Eosinophils pretreated with PGD2 no longer respond to 15d-PGJ2, and vice versa, but in both cases the cells still respond to another eicosanoid proinflammatory mediator, 5-oxo-6,8,11,14-eicosatetraenoic acid. This indicates that the effects of 15d-PGJ2 are mediated by the DP2/chemoattractant receptor-homologous molecule expressed on Th2 cells that has recently been identified in eosinophils. 15d-PGJ2 is selective for the DP2 receptor, in that it has no effect on DP1 receptor-mediated adenylyl cyclase activity in platelets. We conclude that 15d-PGJ2 and 15d-PGD2 are selective DP2 receptor agonists that activate human eosinophils with potencies at least 100 times greater than those for the proposed anti-inflammatory effects of 15d-PGJ2 on other cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
Funk, C. D. (2001) · Science · doi:10.1126/science.294.5548.1871 · Cited by 3,817
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Lipid mediator class switching during acute inflammation: signals in resolution
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001) · Nature Immunology · doi:10.1038/89759 · Cited by 1,453 · cited 1×
“In contrast, most of the eicosanoids formed by the 5-lipoxygenase pathway, including leukotriene B4, the cysteinyl-leukotrienes, and 5-oxoETE, appear to have strictly proinflammatory effects (46), with the exception of the lipoxins, which are highly potent antiinflammatory agents at nanomolar or subnanomolar concentra…”
BackgroundChawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069 · cited 1×
“Although 15d-PGJ2 does not activate the DP1 receptor, relatively high concentrations of this substance can inhibit macrophages and other cells by both PPAR and non-receptor-mediated mechanisms (4, 6, 29).”
BackgroundChinetti, G., Fruchart, J.-C., & Staels, B. (2000) · Inflammation Research · doi:10.1007/s000110050622 · Cited by 954 · cited 13×
“These proinflammatory effects are in contrast to a variety of anti-inflammatory effects (4, 25, 26) reported for this compound, which appear to be mediated by two major mechanisms: activation of PPAR (27, 28); and direct interaction with protein thiol groups as a result of its reactive dienone system (10, 12, 28).”
BackgroundInfluential
Cited by
Woodward, D. F., Jones, R. L., & Narumiya, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003517 · Cited by 443
15d-PGJ2: The anti-inflammatory prostaglandin?
Scher, J. U., & Pillinger, M. H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.09.008 · Cited by 348
Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases
Pettipher, R., Hansel, T. T., & Armer, R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2266 · Cited by 317
Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis
Wiley, C. D., Sharma, R., Davis, S. S., Lopez-Dominguez, J. A., Mitchell, K. P., Wiley, S., Alimirah, F., Kim, D. E., Payne, T., Rosko, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.008 · Cited by 173
PPAR and Immune System-What Do We Know?
Zhang, X., & Young, H. A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00057-7 · Cited by 123
Metadata
- Authors
- Monneret, G., Li, H., Vasilescu, J., Rokach, J., & Powell, W. S.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-04-01
- Volume
- 168
- Issue
- 7
- Pages
- 3563-3569
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2160634538
- Cited by
- 112
- References
- 7
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 15-Deoxy-Δ12,1412,14-prostaglandins D2 and J2 Are Potent Activators of Human Eosinophils. https://app.cochat.ai/papers/10.4049/jimmunol.168.7.3563
- The paper
- Monneret, G., Li, H., Vasilescu, J., Rokach, J., & Powell, W. S. (2002). 15-Deoxy-Δ12,1412,14-prostaglandins D2 and J2 Are Potent Activators of Human Eosinophils. The Journal of Immunology. https://doi.org/10.4049/jimmunol.168.7.3563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.